USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Orega Biotech

USPTO PatentsView assignee record - 5 granted patents across 6 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

RSS updates for this company

The verdict

According to USPTO PatentsView, Orega ranks #49,368 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 6 technology areas.

#49,368
of 49,997 US assignees by volume
44th percentile
by Innovation Score (33.3/100)
19.6
avg claims per patent
-67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R49368 · Foreign Corporation #49,368 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #49,368/49,997
  • PHOTO-FINISH Opus RV Pty
  • CPC-NARROW C07K · 6 areas
  • INNOV-THIN 33.3/100
  • CLAIMS-RICH 19.6 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -67% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Opus RV Pty Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Orega’s 33.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Orega

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Orega's Innovation Score is 33.3/100 (44th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Orega?

Each dot is one of Orega’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Orega’s own 19.6 claims/patent is ABOVE the 12.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Orega vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 4.95.05.055.05.05.1 0510152025 Granted patents (volume) Avg claims / patent Opus RV Pty Ltd - 5, 1Opus RV PtyOralKleen, LLC - 5, 4.8OralkleenOrbSurgical Ltd. - 5, 23.4OrbsurgicalOrbis Canada Limited - 5, 19.4Orbis CanadaOrganized Living, Inc. - 5, 9.8Organized LivingOrganofuel Sweden AB - 5, 16.6Organofuel Sweden…Origyn LLC - 5, 13.4OrigynOrkus Swim LLC - 5, 12.2Orkus SwimOrega Biotech - 5, 19.6Orega Biotech
Orega vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Orega's grants concentrate

Orega Biotech is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2017 (2 grants) versus a trough of 1 in 2019. By volume, Orega sits between Opus RV Pty Ltd and Orkus Swim LLC.

Orega's three-year grant acceleration

Orega Biotech shows 1 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Orega's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Orega holds 5 patents at rank #49,409, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Orega

By rank, the assignees closest to #49,409 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Orega's primary technology class.

Orega's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 44th percentile higher than 44% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 2017201920232025 1
USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Orega Biotech patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 2 40.0%
2019 1 20.0%
2023 1 20.0%
2025partial year 1 20.0%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Orega Biotech's patent record in context - here's where to go next.

  • Orega Biotech's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
  • Ranked #49,368 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Orega Biotech against Opus RV Pty Ltd, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 33.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.